Abstract
Purpose: This study aimed to develop a new prognostic model for predicting 30-day mortality in cancer patients with suspected infection.Methods: This study is a retrospective cohort study and was conducted from August 2019 to December 2019 at a single center. Adult active cancer patients with suspected infection were enrolled among visitors to the emergency room (ER). Logistic regression analysis was used to identify potential predictors for a new model. Results: A total of 899 patients were included; 450 in the development cohort and 449 in the validation cohort. Six independent variables predicted 30-day mortality: Eastern Cooperative Oncology Group (ECOG) performance status (PS), peripheral oxygen saturation (SpO2), creatinine, bilirubin, C-reactive protein (CRP), and lactate. The C-statistic of the new scoring system was 0.799 in the development cohort and 0.793 in the validation cohort. The C-statistics in the development cohort was significantly higher than those of SOFA [0.723 (95% CI: 0.663–0.783)], qSOFA [0.596 (95% CI: 0.537–0.655)], and SIRS [0.547 (95% CI: 0.483–0.612)]. Conclusions: The discriminative capability of the new cancer-specific risk scoring system was good in cancer patients with suspected infection. The new scoring system was superior to SOFA, qSOFA, and SIRS in predicting mortality.
Clinical trial of intraperitoneal hyperthermic perfusion under low temperature anesthesia combined with surgery for gastric cancer patients with peritoneal seeding or serosal invasion.
